Clinical Trials Sponsored by Keystat, LLC

Total 10740 results

Vitrac Therapeutics, LLC
Westat

Terminated

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
R-Pharm Overseas, Inc.
Data Management 365; Keystat, LLC

Not yet recruiting

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Recurrent Pericarditis

United States
R-Pharm Overseas, Inc.
R-Pharm; Data Management 365; Cromos Pharma LLC; Keystat, LLC; K-Research

Completed

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Acute ST Segment Elevation Myocardial Infarction

United States, Russian Federation
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Advanced Cancer | Solid Tumor, Adult | Metastatic Osteosarcoma | Metastatic Sarcoma | Metastatic Hepatocellular Carcinoma | Lung Cancer, Small Cell

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

Cystic Fibrosis

United States
Krystal Biotech, Inc.

Completed

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB (GEM-3)

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Krystal Biotech, Inc.

Active, not recruiting

Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

TGM-1 Related Autosomal Recessive Congenital Ichthyosis

United States
Krystal Biotech, Inc.

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (Serpentine-1)

Alpha 1-Antitrypsin Deficiency

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Cancer | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Osteosarcoma | Cutaneous Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Krystal Biotech, Inc.

Not yet recruiting

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Autosomal Recessive Ichthyosis

United States
Krystal Biotech, Inc.

Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Krystal Biotech, Inc.

Recruiting

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Wrinkle | Skin Roughness | Fine Lines | Skin Thickness

United States
Krystal Biotech, Inc.

Active, not recruiting

Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa (GEM-1)

Dystrophic Epidermolysis Bullosa

United States
Mundipharma SAS
AXONAL; Exystat

Completed

Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma (Pen ASAP)

Pain, Acute

France
Vascular Solutions LLC
Westat; United States Army Medical Materiel Development Activity

Not yet recruiting

Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin

Anticoagulant Reversal

United States
Westat
Makerere University

Completed

Reintegration of Children Into Family-based Care in Uganda

Parenting

Uganda
TaiMed Biologics Inc.
Westat

Completed

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

HIV-1-infection

United States
TaiMed Biologics Inc.
Westat

Completed

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

HIV-1-infection

United States, Puerto Rico
ImCheck Therapeutics
ILife Consulting; Exystat

Recruiting

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Solid Tumor, Adult

France
Krystal Biotech, Inc.
Stanford University

Withdrawn

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
New York University
Westat

Active, not recruiting

Optimizing an Evidence-Based, Disseminable, Free Internet-Based Parenting Program

Parenting Practices

United States
Arthritis Northwest PLLC
Epigenesys LLC

Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Arthritis, Rheumatoid

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
TaiMed Biologics Inc.
Westat

Completed

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

HIV

United States, Puerto Rico
Krystal Parker, PhD

Recruiting

Cerebellar Stimulation and Cognitive Control

Depression | Schizophrenia | Parkinson Disease | Bipolar Disorder | Autism Spectrum Disorder

United States
Andrew Krystal
Yale University

Withdrawn

FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study (KOR1)

Anxiety Disorders

United States
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
LLS PedAL Initiative, LLC
Kura Oncology

Not yet recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Relapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
Julie Krystal
Janssen Pharmaceuticals

Recruiting

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Glioblastoma Multiforme | Gliosarcoma | Anaplastic Astrocytoma | Pleomorphic Xanthoastrocytoma | Pilocytic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Low-grade Glioma | DIPG | Brainstem Glioma | Optic Nerve Glioma | Pilomyxoid Astrocytoma | Glioma, Astrocytic

United States
Andrew Krystal

Recruiting

Closed-Loop Deep Brain Stimulation for Major Depression (PReSiDio)

Major Depressive Disorder

United States
Krystal Biotech, Inc.
Novotech (Australia) Pty Limited

Withdrawn

A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

Cystic Fibrosis

Australia
Albany Molecular Research, Inc.
Westat

Terminated

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

Cancer

United States
Westat
United States Social Security Administration

Completed

Supported Employment Demonstration (SED)

Mental Impairment

United States
Boston University
University of Florida; Westat

Withdrawn

Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin (DAZZLE)

Tuberculosis Multi Drug Resistant Active
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Redx Pharma Plc
Merck Sharp & Dohme LLC

Completed

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86)

Advanced Solid Tumours

United Kingdom, Australia
4D pharma plc
Merck Sharp & Dohme LLC

Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Oncology

United States
IntegraGen SA
Federation Francophone de Cancerologie Digestive; Exystat

Completed

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Colorectal Cancer
IVFarma LLC
BridgePharm LLC; GlobalPharma LLC

Completed

Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Infertility, Female

Russian Federation
Montefiore Medical Center
Johns Hopkins University; Westat

Completed

RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers (PSFW+)

Tobacco Use Disorder | HIV

United States
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Pharmtechnology LLC
ClinPharmInvest, LLC

Completed

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Bioequivalence

Russian Federation
Monsoon Design Studio LLC
Healthark Wellness Solutions LLP

Completed

Study of Evoked Emotional Responses

Emotion, Expressed

India

Clinical Trials Sponsored by Keystat, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations